JAK2 and myelofibrosis: The mutations that confer activation of the intracellular Janus kinase (JAK) signal transducer and activator of transcription (STAT) pathways (e.g., JAK2, V617F, and JAK2 exon 12) were identified as the most common in patients with myelofibrosis (MF).